Building a Business Empire with my Technological System

Chapter 165: Medipod in Action

December 2nd, 2026, Evening

As the Medipod hummed to life, the atmosphere in the control room of the Benavides Cancer Institute was one of focused anticipation. Dr. Villanueva stared intently at the monitors displaying Marian's vital signs. The Medipod had begun its precise and targeted treatment of Marian's cancerous cells.

Inside the pod, Marian lay still, her breaths measured as the cooling system inside the Medipod maintained a comfortable temperature, countering the warmth generated by the high-intensity treatment. The soft whir of the machine blended with the occasional beep of the heart rate monitor.

Dr. Villanueva adjusted the settings on the console before him, optimizing the nanoparticle flow and monitoring their progress through the live feed. The nanoparticles, engineered at a molecular level to seek out and destroy only cancer cells, were shown as bright specks on the screen, converging on their targets with lethal precision.

"This is remarkable," Dr. Villanueva muttered to himself as he observed the cancer cells beginning to absorb the nanoparticles. The screen displayed the nanoparticles attaching to the cancer cells and releasing a potent cytotoxic agent that initiated cell apoptosis without harming the surrounding healthy tissues.

On another screen, graphs and charts plotted the real-time efficacy of the treatment, showing a significant reduction in the metabolic activity of the cancer cells.

"We're seeing a rapid decrease in the cellular activity of the tumor," he announced to his team, who were equally engrossed in the data streaming in.

Marian's vital signs remained stable, which minimized the physical stress of the treatment on the patient. Dr. Villanueva periodically checked the levels of inflammatory markers and cytokines in Marian's bloodstream, indicators that would signal any adverse response her body might have to the treatment.

As the minutes ticked by, the initial phase of the Medipod operation concluded successfully. Dr. Villanueva allowed himself a brief smile before turning back to his team.

"Prepare for the second phase, increase the dosage incrementally according to the protocol we developed."

Somewhere, a small group of observers, including a few medical professionals, watched in awe. The live data indicated a successful targeting and reduction of tumor mass, potentially validating the Medipod as a revolutionary cancer treatment.

"I can't believe it," said the doctor.

"Are we witnessing history unfolding?" asked another observer quietly, eyes fixed on the screens displaying the promising results.

"This is just too much," another person chimed. "Michael Reyes was nothing but a mechanical engineering student yet was able to invent something as extraordinary as this."

"It's the work of the genius. I wonder how pharmaceutical companies focusing on the treatment of cancer would react if they were to see the Medipod in action?"

"A decrease in sales, and perhaps maybe some sort of a plot that will shut Michael Reyes and technology down?"

"That is impossible given that there are too many cancer patients who are in high-ranking positions and status that would demand access to this technology if it proves to be effective. The potential for this kind of treatment is just too significant to be ignored or suppressed," another observer commented, reflecting on the broader implications of the Medipod's success.

"Still, it happens in history, that technological innovations were sometimes bogged down or worse, completely suppressed by those with vested interests in maintaining the status quo," an observer mused thoughtfully.

"However, given the transparent and open manner in which these trials are being conducted, along with the undeniable potential benefits demonstrated, it might be difficult for anyone to justify shutting it down without facing public and professional backlash."

"That is true. This technology is something that can't be put down just because of competing interests. The data speaks for itself," others added, addressing the observers.

Back in the room, Dr. Villanueva continued monitoring and then speaking out about the progress of the session.

"The subject is responding extremely well to the treatment. We are currently observing a significant apoptosis rate in the targeted cells," Dr. Villanueva reported as he pointed to a series of charts on the display. "Look at these necrosis markers, they're declining, and the angiogenesis around the tumor mass has significantly slowed down."

He shifted his attention back to another monitor showing a 3D model of the tumor. "You can see here the precise targeting of the nanoparticles. They are effectively binding to the overexpressed receptors on the cancer cells, and the release of cytotoxins is directly within the tumor microenvironment.

This localized approach minimizes systemic toxicity, which is a major advantage over traditional chemotherapy."

One of the technicians adjusted a dial slightly, fine-tuning the nanoparticle density. Dr. Villanueva nodded in approval.

"Good, keep the flow rate steady, and let's monitor the off-target effects closely. We don't want to see significant elevations in liver enzymes or cytokine levels."

As they continued the session, Dr. Villanueva periodically checked Marian's vitals. "Her heart rate and blood pressure are stable, which is excellent. Also, there's no significant elevation in her C-reactive protein, which indicates that inflammation is under control. This is exactly what we want to see during such a targeted therapy session."

After a pause, he continued explaining to the observing interns, "This phase of treatment focuses on sustaining the cytotoxic attack while managing the immune response. It's a delicate balance, but the Medipod's real-time monitoring and adaptive algorithms allow us to maintain optimal treatment parameters."

Glancing back at the screen, Dr. Villanueva's expression remained composed but optimistic as he watched the real-time data, "The tumor's metabolic activity continues to decrease. This is consistent with effective oncotic pressure and disruption of the cancer cell's ability to replicate. We are essentially watching the cancer being eradicated at the cellular level."

"As we conclude this session," Dr. Villanueva addressed his team, "we'll prepare for a detailed analysis of the tumor tissue through biopsies. The histological examination will give us further insights into the cellular changes and confirm the extent of apoptosis and any residual activity of the cancer cells."

The treatment session gradually drew to a close, and the team began the process of safely extracting Marian from the Medipod. Dr. Villanueve stepped forward and asked.

"How are you feeling?"

Marian, emerging from the Medipod, looked visibly tired but there was a faint glimmer of relief in her eyes. She took a moment to gather her thoughts before responding.

"I feel... lighter, somehow. Less burdened," she said, trying to express the subtle changes she sensed within her body.

He then continued to explain the next steps. "We'll keep monitoring your vitals and the tumor markers over the coming weeks. You'll have regular follow-ups to assess how the tumor is responding to the treatment and to check for any potential side effects. It's crucial that you report anything out of the ordinary."

Marian nodded, absorbing the information. "Thank you, Doctor. For everything."

Dr. Villanueva offered a reassuring smile. "Of course, Marian. We're here to support you through this."

As Marian was wheeled out of the treatment room, Dr. Villanueva turned back to his team. "Alright, everyone, let's compile the data and prepare the initial report. We need a comprehensive analysis of today's session. I want everything documented, from the nanoparticle efficiency to Marian's physiological responses."

"Yes doctor!"